NeuroMetrix, Inc. (NURO) Value Adjusted for Debt and Cash

Risks of low insurance reimbursement and declining demand for legacy systems are weighing on the capitalization of NeuroMetrix, Inc. (NURO), while a lack of funding is hindering growth. Meanwhile, NeuroMetrix, Inc. (NURO) develops wearable devices for neuropathy therapy, generating revenue from software and consumables. The share price visualized below on GURU.Markets is . Revenue stability is driven by the sale of electrodes and support for devices used to combat chronic pain.

For NeuroMetrix, Inc. (NURO), which maintains a lean engineering staff during its transformation period, a business valuation analysis allows for an assessment of the asset's real price excluding temporary operating expenses. The Enterprise Value (EV) trend aggregates market capitalization and debt obligations minus cash, helping investors determine whether the company is fundamentally overvalued or undervalued in the event of a potential full acquisition.